Clinical Trial Update: The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121) [Phase 3]

View source ↗

Summary

The HERO study is a Phase 3 trial evaluating roflumilast in patients with chronic obstructive pulmonary disease (COPD); the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease, COPD | Phase 3 | Status: COMPLETED